Add Haloperidol linked cogwheel rigidity in package insert: CDSCO Panel

While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the dopamine receptor (mainly D2), particularly within the mesolimbic and mesocortical systems of the brain.

Haloperidol is indicated for the treatment of the manifestations of several psychotic disorders including schizophrenia, acute psychosis, Tourette syndrome, and other severe behavioural states.

A few brands of Haloperidol include Torrent Pharma's Hexidol (1.5 mg), Sun Pharma's Senorm (10 mg,5mg), Intas Pharma's Trancodol (1.5 mg), etc.

At a recent SEC meeting for Neurology & Psychiatry, the recommendation of the signal review panel, PVPI, IPC, was placed before the committee regarding the adverse reaction of Haloperidol associated cogwheel rigidity.

In view of the above, after detailed deliberation, the committee recommended,

"CDSCO should request the State Drugs Controllers to direct the manufacturers to include ADR of Haloperidol associated cogwheel rigidity in the package insert of the drug marketed in the country."